The Cutting Edge of Medical Technology Content, Community & Collaboration
SBIR Re-Authorization/Changes Appear to be Imminent
Colleagues,
As noted in the excellent "SBIR Insider" newsletter ... Congressional Committees appear to be close to reaching a conclusion on the protracted SBIR (Small Business Innovative Research), STTR (Small Business Technology Transfer Research) reauthorization process.
As many MedTech-IQ members may be aware, the issue of including Venture Capital (VC) backed companies in the programs has been the main stumbling block. The House Committee appears to be leaning towards extending eligibility to VC backed companies.
At the time of this writing, the Senate Reauthorization bill proposes the following changes in the programs:
Important points include:
* * Increase SBIR allocation by 0.1% per year (starting in FY-2011) until reaching 3.5% in FY-2020
* Increase STTR allocation to .4% for FY-2011; .5% for FY-2013; 0.6% for FY-2015
* Increase SBIR/STTR award levels to $150k phase I and $1M for phase II
* Awards shall not exceed 50% above recommended award levels
* Elimination of Phase II "invitation" process (i.e., DoD)
* VC small biz eligibility compromise limited to 18% of NIH SBIR Award funding, 8% at the other 10 agencies
* Allow small business to partner with federal labs or FFRDC without requiring a wavier from SBA
* Reinstate State and Rural outreach programs
* SBIR STEM Workforce Development Grant Pilot Program
* Continuation of Commercialization Pilot Program (DoD)
* Establish Commercialization Pilot Program for civilian agencies
* Nanotechnology Initiative
* Accelerating Cures - NIH Pilot
* Increase in technical assistance from $4k to $5k
* SBIR and STTR Special Acquisition Preference
Both the House and Senate are likely to act on their various versions of the bill in the next few weeks.
ENJOY!
CC
As noted in the excellent "SBIR Insider" newsletter ... Congressional Committees appear to be close to reaching a conclusion on the protracted SBIR (Small Business Innovative Research), STTR (Small Business Technology Transfer Research) reauthorization process.
As many MedTech-IQ members may be aware, the issue of including Venture Capital (VC) backed companies in the programs has been the main stumbling block. The House Committee appears to be leaning towards extending eligibility to VC backed companies.
At the time of this writing, the Senate Reauthorization bill proposes the following changes in the programs:
Important points include:
* * Increase SBIR allocation by 0.1% per year (starting in FY-2011) until reaching 3.5% in FY-2020
* Increase STTR allocation to .4% for FY-2011; .5% for FY-2013; 0.6% for FY-2015
* Increase SBIR/STTR award levels to $150k phase I and $1M for phase II
* Awards shall not exceed 50% above recommended award levels
* Elimination of Phase II "invitation" process (i.e., DoD)
* VC small biz eligibility compromise limited to 18% of NIH SBIR Award funding, 8% at the other 10 agencies
* Allow small business to partner with federal labs or FFRDC without requiring a wavier from SBA
* Reinstate State and Rural outreach programs
* SBIR STEM Workforce Development Grant Pilot Program
* Continuation of Commercialization Pilot Program (DoD)
* Establish Commercialization Pilot Program for civilian agencies
* Nanotechnology Initiative
* Accelerating Cures - NIH Pilot
* Increase in technical assistance from $4k to $5k
* SBIR and STTR Special Acquisition Preference
Both the House and Senate are likely to act on their various versions of the bill in the next few weeks.
ENJOY!
CC
Views: 0
MedTechIQ VideoLibrary
Upcoming Events
© 2024 Created by CC-Conrad Clyburn-MedForeSight.
Powered by
